ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.20) by 55 percent. This is a 74.29 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $7.55 million which missed the analyst consensus estimate of $7.82 million by 3.39 percent. This is a 5.33K percent increase over sales of $139.00 thousand the same period last year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。